Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Managing Hodgkin lymphoma – a world view (from ISHL 2016)

Written by | 28 Nov 2016

by Christine Clark ISHL 2016 Professor Joseph Connors (Vancouver) speaks about the session at ISHL10 where a world view of the management of Hodgkin lymphoma was discussed. There… read more.

ESH ICMM Highlights

Written by | 3 Oct 2016

Professor Mohamad Mohty (Paris), Professor Sagar Lonial  (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.

ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

Written by | 10 Feb 2016

Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

ASH 2015: Ernest Beutler Lecture Prize: Award-winners trace history of proteasome and its starring role in MM treatment: Interview with Alfred Goldberg, PhD, Professor of Cell Biology at Harvard Medical School, and Paul Richardson, MD, Professor of Medicine at the Dana-Farber Cancer Center

Written by | 8 Feb 2016

by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.

ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

Written by | 25 Jan 2016

Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

ASH 2015: New therapies explored in peripheral T-cell lymphoma

Written by | 19 Jan 2016

by Thomas R. Collins: In early results, patients newly diagnosed with peripheral T-cell lymphoma (PTCL) treated with the HDAC-inhibitor belinostat, and CHOP therapy, tolerated the combination well at… read more.

ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results

Written by | 13 Jan 2016

by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.

ASH 2015: Trials exploring new settings for monoclonal antibodies in MM

Written by | 12 Jan 2016

by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.

ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

Written by | 30 Dec 2015

by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

ASH 2015: Prognostic score helps assess chances of progression-free survival in HL autologous transplant recipients

Written by | 28 Dec 2015

by Thomas R. Collins: Researchers have developed a prognostic “score” to gauge the chances of progression-free survival in patients with relapsed or refractory Hodgkin lymphoma who have had… read more.

IMV 2015 Debate: Professors Faith Davies, Gareth Morgan (both UAMS) and Sagar Lonial (Atlanta) discuss the importance of combination therapy. Professor Faith Davies from UAMS and Professor Shaji Kumar from Mayo Clinic faced one another in a debate over the respective benefits of combination therapy and sequential therapy in MM…

Written by | 13 Nov 2015

Specialists in the MM field are in the enviable position of having lots of different treatment options available – the challenge is how to integrate these into the… read more.

BSH 2015: COSD and SACT Cancer Data: How do you perform/conform nationally? Robin Ireland, Kings College Hospital, London.

Written by | 3 Jun 2015

by Christine Clark: The National Cancer Information Network (NCIN) was established to drive change and improve cancer outcomes. Analyses show large variations in practices and outcomes some of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.